Joshua Cohen

Policy experts suggest reform of prior authorization that would require coverage decisions be supported solely by evidence being reviewed by independent clinicians.

May 4, 2026 – “The man was writing like his typewriter was on fire and in flaming succession produced three books that have been called a trilogy through proximity alone.”

Despite more than two decades of safe and effective use, the abortion pill is once more in the crosshairs of American politics and the judicial system.

The White House issued a report this week touting massive projected cost savings — more than $500 billion over a ten-year period — from so-called

Hearings on healthcare on Capitol Hill often devolve into partisan grandstanding on both sides of the aisle.

Should Medicare change the default option for new beneficiaries to Medicare Advantage or an ACO, this could backfire as costs could rise and access restrictions increase.

During a tumultuous 13-month tenure at the FDA, Makary pursued a wide range of ambitious initiatives. Going forward, their status under the next commissioner is unclear.

Those with a vested interest in the status quo, are resisting transparency regulations. After all, maintaining opaque pricing in healthcare has been profitable to them.

High level resignations in protest against the push to allow sales of fruit-flavored vapes suggest a break in policy between the first and second Trump administrations.

White House model estimates on cost savings from most-favored nation drug prices are speculative and depend on a set of unrealistic assumptions.